ID   BEL-7402
AC   CVCL_5492
SY   Bel-7402; BEL 7402; Bel 7402; BEL7402; Bel7402
DR   BTO; BTO:0004050
DR   ChEMBL-Cells; CHEMBL3307770
DR   ChEMBL-Targets; CHEMBL614279
DR   Cosmic; 1499247
DR   Cosmic; 2773179
DR   GEO; GSM936754
DR   GEO; GSM1374400
DR   PRIDE; PXD015917
DR   PubChem_Cell_line; CVCL_5492
DR   TOKU-E; 3571
DR   Wikidata; Q54795968
RX   DOI=10.1007/978-4-431-68349-0_4;
RX   PubMed=1849045;
RX   PubMed=6154311;
RX   PubMed=6275024;
RX   PubMed=14571772;
RX   PubMed=23167424;
RX   PubMed=23505090;
RX   PubMed=28807831;
CC   Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=28807831). Originally thought to originate from a 53 year old male patient with a hepatocellular carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00549.
CC   Population: African American.
CC   Doubling time: 20 hours (PubMed=6154311); 31.2 +- 1.1 hours (PubMed=23167424).
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Miscellaneous: Formerly the CCRID database had 2 entries describing this cell line (3131C0001000700010, 3142C0001000000035). They were the sole source for the STR profile of this entry.
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): CCRID
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 13.3
ST   D16S539: 9,10
ST   D18S51: 16
ST   D19S433: 13
ST   D21S11: 27,28
ST   D2S1338: 17
ST   D3S1358: 15,18
ST   D5S818: 12
ST   D7S820: 12
ST   D8S1179: 12
ST   FGA: 18,21
ST   TH01: 7
ST   TPOX: 12
ST   vWA: 16,18
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0030 ! HeLa
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
RX   DOI=10.1007/978-4-431-68349-0_4;
RA   Alexander J.J.;
RT   "Human hepatoma cell lines.";
RL   (In) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo (1987).
RX   PubMed=1849045;
RA   Fuhrer J.P., Xie H., Murphy M.J. Jr., Ye J.N., Yao Z.;
RT   "Characterization of a membrane-associated glycoprotein (gp 43) on
RT   human hepatocellular carcinoma by a monoclonal antibody.";
RL   Cancer Res. 51:2158-2163(1991).
RX   PubMed=6154311; DOI=10.1360/ya1980-23-2-236;
RA   Chen R.-M., Zhu D.-H., Ye X.-Z., Shen D.-W., Lu R.-H.;
RT   "Establishment of three human liver carcinoma cell lines and some of
RT   their biological characteristics in vitro.";
RL   Sci. Sin. 23:236-247(1980).
RX   PubMed=6275024; DOI=10.1099/0022-1317-57-1-95;
RA   Koshy R., Maupas P., Muller R., Hofschneider P.H.;
RT   "Detection of hepatitis B virus-specific DNA in the genomes of human
RT   hepatocellular carcinoma and liver cirrhosis tissues.";
RL   J. Gen. Virol. 57:95-102(1981).
RX   PubMed=14571772;
RA   Liu L.-X., Jiang H.-C., Liu Z.-H., Zhu A.-L., Zhou J., Zhang W.-H.,
RA   Wang X.-Q., Wu M.;
RT   "Gene expression profiles of hepatoma cell line BEL-7402.";
RL   Hepato-Gastroenterol. 50:1496-1501(2003).
RX   PubMed=23167424; DOI=10.7314/APJCP.2012.13.9.4807;
RA   Gu W., Fang F.-F., Li B., Cheng B.-B., Ling C.-Q.;
RT   "Characterization and resistance mechanisms of a
RT   5-fluorouracil-resistant hepatocellular carcinoma cell line.";
RL   Asian Pac. J. Cancer Prev. 13:4807-4814(2012).
RX   PubMed=23505090; DOI=10.1002/hep.26402;
RA   Wang K., Lim H.Y., Shi S., Lee J., Deng S., Xie T., Zhu Z., Wang Y.,
RA   Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.;
RT   "Genomic landscape of copy number aberrations enables the
RT   identification of oncogenic drivers in hepatocellular carcinoma.";
RL   Hepatology 58:706-717(2013).
RX   PubMed=28807831; DOI=10.1016/j.jhep.2017.08.002;
RA   Rebouissou S., Zucman-Rossi J., Moreau R., Qiu Z.-X., Hui L.-J.;
RT   "Note of caution: contaminations of hepatocellular cell lines.";
RL   J. Hepatol. 67:896-897(2017).